FBRSL1: A Potential Drug Target and Biomarker (G57666)

Target Name: FBRSL1

NCBI ID: G57666

FBRSL1

FBRSL1: A Potential Drug Target and Biomarker

Fibrosin like 1 (FBRSL1), also known as transcript variant 1, is a protein that is expressed in various tissues, including heart, lungs, kidneys, and intestines. FBRSL1 is a member of the fibroblast growth factor family, which is a group of proteins that are involved in cell growth, differentiation, and repair.

FBRSL1 has been identified as a potential drug target due to its involvement in several diseases, including heart failure, cancer, and neurodegenerative diseases. FBRSL1 has also been shown to be overexpressed in various types of cancer, which suggests that it may have a role in the development and progression of these diseases.

One of the key challenges in studying FBRSL1 is its complex structure and function. Despite its clear conserved sequence, the precise three-dimensional structure of FBRSL1 is not well understood. However, recent studies have used various techniques, such as yeast two-hybrid and protein- fragment complementation assays, to determine that FBRSL1 has a unique structural domain, known as the N-terminal alpha-helix, which is involved in its function.

Additionally, FBRSL1 has been shown to play a role in several signaling pathways, including the TGF-β pathway and the Wnt pathway. This suggests that it may be a useful target for drugs that are designed to modulate these pathways. For example, studies have shown that inhibitors of the TGF-β pathway can be effective in treating breast and ovarian cancers, which are often associated with TGF-β signaling.

Another potential mechanism by which FBRSL1 may be targeted is its role in cell-cell adhesion. FBRSL1 has been shown to be involved in the formation of tight junctions, which are a type of cell-cell adhesion structure. This suggests that drugs that are able to disrupt tight junctions may be effective in treating diseases that are characterized by cell-cell adhesion, such as cancer.

FBRSL1 has also been shown to be involved in several signaling pathways that are involved in cell growth and differentiation. For example, studies have shown that FBRSL1 is involved in the regulation of the Notch pathway, which is involved in the development and maintenance of neural stem cells. Additionally, FBRSL1 has been shown to be involved in the regulation of the Wnt pathway, which is involved in the development and maintenance of tissues that are involved in development and growth, such as muscles and organs.

Despite the potential benefits of targeting FBRSL1, there are also several potential drawbacks to consider. One of the main challenges is the potential for adverse effects associated with targeting a protein that is involved in so many different signaling pathways. Additionally, there may be other proteins that are similar to FBRSL1 that could be targeted instead, which could limit the effectiveness of any potential drug candidates.

Overall, FBRSL1 is a protein that has the potential to be a drug target due to its involvement in several diseases and signaling pathways. While further research is needed to fully understand its function and potential as a drug target, studies have shown that it is an promising target for future research.

Protein Name: Fibrosin Like 1

The "FBRSL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBRSL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets